<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">33490355</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2352-5789</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>35</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gynecologic oncology reports</Title>
          <ISOAbbreviation>Gynecol Oncol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies in an ovarian cancer case: A case report.</ArticleTitle>
        <Pagination>
          <StartPage>100695</StartPage>
          <MedlinePgn>100695</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">100695</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gore.2020.100695</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic neurologic syndromes (PNS) are a rare heterogeneous group of disorders associated with malignancy that can result in significant functional impairment. One syndrome in particular, paraneoplastic cerebellar degeneration (PCD), may be severely disabling. PCD is a rare neurological syndrome, associated with active or subclinical cancer, characterized by acute or subacute onset cerebellar ataxia due to tumor-induced autoimmunity against cerebellar antigens. Treatment of paraneoplastic syndromes is generally unsatisfactory, but early diagnosis and treatment of PCD, which includes neurological treatment, immunotherapy and oncological treatment of associated malignancy, may improve the neurological prognosis. We reported the case of a 59-year-old woman who presented PCD as the first sign of ovarian cancer. Laboratory investigations showed the presence of anti-Yo antibodies in the serum. The brain MRI revealed specific modifications for PCD. After oncological treatment, intravenous immunoglobulin therapy and corticosteroid therapy, the oncological response was satisfactory, but no improvement of the neurologic symptoms was achieved.</AbstractText>
          <CopyrightInformation>© 2021 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Deac</LastName>
            <ForeName>Sandra</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Institute "Ion Chiricuta", Medical Oncology Department, Cluj Napoca, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stana</LastName>
            <ForeName>Mihaela Marioara</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Institute "Ion Chiricuta", Medical Oncology Department, Cluj Napoca, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Havasi</LastName>
            <ForeName>Andrei Dan</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Institute "Ion Chiricuta", Medical Oncology Department, Cluj Napoca, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cainap</LastName>
            <ForeName>Calin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Institute "Ion Chiricuta", Medical Oncology Department, Cluj Napoca, Romania.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Popita</LastName>
            <ForeName>Anca-Raluca</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Institute "Ion Chiricuta", Radiology and Medical Imaging Department, Cluj Napoca, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bordeianu</LastName>
            <ForeName>Ana Maria</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>RoNEURO Institute, Cluj-Napoca, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cainap</LastName>
            <ForeName>Simona</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mother and Child, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bota</LastName>
            <ForeName>Madalina</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mother and Child, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bochis</LastName>
            <ForeName>Ovidiu Vasile</ForeName>
            <Initials>OV</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Institute "Ion Chiricuta", Medical Oncology Department, Cluj Napoca, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Gynecol Oncol Rep</MedlineTA>
        <NlmUniqueID>101652231</NlmUniqueID>
        <ISSNLinking>2352-5789</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-Yo antibodies</Keyword>
        <Keyword MajorTopicYN="N">Gynecological cancer</Keyword>
        <Keyword MajorTopicYN="N">Ovarian cancer</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic syndromes</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>5</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33490355</ArticleId>
        <ArticleId IdType="pmc">PMC7808941</ArticleId>
        <ArticleId IdType="doi">10.1016/j.gore.2020.100695</ArticleId>
        <ArticleId IdType="pii">S2352-5789(20)30161-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327–340. doi: 10.1016/S1474-4422(08)70060-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70060-7</ArticleId>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. Ann. Indian Acad. Neurol. 2012;15(1):6–12. doi: 10.4103/0972-2327.93267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0972-2327.93267</ArticleId>
            <ArticleId IdType="pmc">PMC3299076</ArticleId>
            <ArticleId IdType="pubmed">22412264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKeon A., Tracy J.A., Pittock S.J., Parisi J.E., Klein C.J., Lennon V.A. Purkinje Cell Cytoplasmic Autoantibody Type 1 Accompaniments: The Cerebellum and Beyond. Arch. Neurol. 2011;68(10):1282–1289. doi: 10.1001/archneurol.2011.128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.128</ArticleId>
            <ArticleId IdType="pubmed">21670387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitoma H., Adhikari K., Aeschlimann D., Chattopadhyay P., Hadjivassiliou M., Hampe C.S. Consensus paper: neuroimmune mechanisms of cerebellar ataxias. Cerebellum. 2016;15:213–232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4591117</ArticleId>
            <ArticleId IdType="pubmed">25823827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Russo A.E., Scalone S., Leonardi G.C., Scalisi A., Giorda G., Sorio R. Paraneoplastic cerebellar degeneration associated with ovarian cancer. Oncol. Lett. 2013;5(2):681–683. doi: 10.3892/ol.2012.1016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2012.1016</ArticleId>
            <ArticleId IdType="pmc">PMC3572954</ArticleId>
            <ArticleId IdType="pubmed">23420048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams'ili S., Grefkens J., de Leeuw B., van den Bent M., Hooijkaas H., van der Holt B., Vecht C., Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003 Jun;126(Pt 6):1409–1418. doi: 10.1093/brain/awg133. PMID: 12764061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg133</ArticleId>
            <ArticleId IdType="pubmed">12764061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vedeler C.A., Antoine J.C., Giometto B., Graus F., Grisold W., Hart I.K., Honnorat J., Sillevis Smitt P.A., Verschuuren J.J., Voltz R. Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur. J. Neurol. 2006 Jul;13(7):682–690. doi: 10.1111/j.1468-1331.2006.01266.x. PMID: 16834698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2006.01266.x</ArticleId>
            <ArticleId IdType="pubmed">16834698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A., Bernardini A., Gigli G.L., Corazza E., Marini A., Segatti S., Fabris M., Honnorat J., Valente M. Stroke-Like Presentation of Paraneoplastic Cerebellar Degeneration: a Single-Center Experience and Review of the Literature. Cerebellum. 2019;18(5):976–982. doi: 10.1007/s12311-019-01075-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-019-01075-9</ArticleId>
            <ArticleId IdType="pubmed">31463826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yshii L., Bost C., Liblau R. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications. Front. Immunol. 2020;11:991. doi: 10.3389/fimmu.2020.00991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00991</ArticleId>
            <ArticleId IdType="pmc">PMC7326021</ArticleId>
            <ArticleId IdType="pubmed">32655545</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
